213 Duplication of chromosome 17 CEP predicts for anthracycline benefit: evidence from an international meta-analysis of 4 adjuvant breast cancer trials for the HER2/TOP2A meta-analysis study group

2010 ◽  
Vol 8 (3) ◽  
pp. 121 ◽  
Author(s):  
J.M.S. Bartlett ◽  
A. Munro ◽  
F.P. O'Malley ◽  
H. Earl ◽  
C.J. Poole ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Meta Analysis ◽  
Chromosome 17 ◽  
Study Group ◽  
Analysis Study ◽  
Adjuvant Breast Cancer ◽  
Cancer Trials

scholarly journals Factors affecting baseline quality of life in two international adjuvant breast cancer trials

1998 ◽  
Vol 78 (5) ◽  
pp. 686-693 ◽  
Author(s):  
J Bernhard ◽  
◽  
C Hürny ◽  
AS Coates ◽  
HF Peterson ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Quality Of Life ◽  
Factors Affecting ◽  
Adjuvant Breast Cancer ◽  
Cancer Trials

Update of the Oxford Overview: New Insight and Perspectives in the Era of Personalized Medicine

2012 ◽  
pp. 71-79
Author(s):  
Kathleen I. Pritchard ◽  
Jonas Bergh ◽  
Harold J. Burstein
Keyword(s):  
Breast Cancer ◽  
Hormone Receptor ◽  
Meta Analysis ◽  
Breast Cancers ◽  
Breast Cancer Therapy ◽  
Hormone Receptor Positive ◽  
Er Positive ◽  
Adjuvant Breast Cancer ◽  
Great Appreciation ◽  
Positive Breast Cancer

Overview: There is great appreciation for the heterogeneity of breast cancers, particularly of hormone-receptor positive breast cancers. A goal of modern oncology managing such heterogeneity is to determine how to individualize therapy based on the specific pathological and biological features of a given tumor. Two distinctive clinical literatures exist to guide treatment of hormone-receptor-positive breast cancer. The Oxford Overview, a seminal meta-analysis effort, has recently been updated, and suggests that nearly all patients with ER-positive tumors benefit from adjuvant endocrine therapy. In addition, the overview finds that nearly all subsets of patients with ER-positive tumors also benefit from modern adjuvant chemotherapy regimens. Meanwhile, retrospective subset analyses of specific trials or populations suggests that the benefits of chemotherapy are not so uniform, and in particular that molecular diagnostics assays can identify patients who do not warrant chemotherapy. This article will highlight recent data and controversies in personalizing adjuvant breast cancer therapy.

Diagnostic value of circulating microRNAs as biomarkers for breast cancer: a meta-analysis study

Tumor Biology ◽  
2014 ◽  
Vol 36 (2) ◽  
pp. 829-839 ◽  
Author(s):  
Zhaolei Cui ◽  
Donghong Lin ◽  
Wenfang Song ◽  
Meihuan Chen ◽  
Dan Li
Keyword(s):  
Breast Cancer ◽  
Meta Analysis ◽  
Diagnostic Value ◽  
Circulating Micrornas ◽  
Analysis Study

scholarly journals Association of osteopontin with specific prognostic factors and survival in adjuvant breast cancer trials of the Hellenic Cooperative Oncology Group

2017 ◽  
Vol 15 (1) ◽  
Author(s):  
Amanda Psyrri ◽  
Konstantine T. Kalogeras ◽  
Ralph M. Wirtz ◽  
George Kouvatseas ◽  
Georgia Karayannopoulou ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Prognostic Factors ◽  
Oncology Group ◽  
Adjuvant Breast Cancer ◽  
Cancer Trials

hOGG1 gene polymorphism and breast cancer risk: A systematic review and meta-analysis study

2017 ◽  
Vol 24 (1) ◽  
pp. 70-73 ◽  
Author(s):  
Ali Sanjari Moghaddam ◽  
Milad Nazarzadeh ◽  
Zeinab Bidel ◽  
Aliasghar Karamatinia ◽  
Hossein Darvish ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Systematic Review ◽  
Breast Cancer Risk ◽  
Cancer Risk ◽  
Gene Polymorphism ◽  
Meta Analysis ◽  
Analysis Study ◽  
Hogg1 Gene
Sign in / Sign up

Export Citation Format

Share Document